ST. Jude Children's Research Hospital Graduate School Of Biomedical Sciences, LLC

ST. Jude Children's Research Hospital Graduate School Of Biomedical Sciences, LLC operates as a tax-exempt nonprofit educational institution and federal grant recipient, performing basic and translational biomedical research in pediatric cancer, immunology, infectious disease, and genetic disorders through National Institutes of Health (NIH) project grants awarded to faculty investigators. The organization acts predominantly as a prime recipient of federal research grants (78% of recent awards) with subordinate engagement as a sub-recipient under Emory University-administered grants, and does not hold federal contracts or contract vehicles.

The graduate school's research portfolio centers on molecular cancer biology, immunotherapy, and rare pediatric disease mechanisms. Representative prime grant work includes investigations into SWI/SNF chromatin remodeling mutations in pediatric rhabdoid tumors and rhabdomyosarcoma (National Cancer Institute), CAR T cell therapy enhancement for diffuse midline glioma combined with magnetic resonance-guided focused ultrasound (National Institute of Neurological Disorders and Stroke), neuroblastoma cell state heterogeneity and chemotherapy resistance (National Cancer Institute), and CRISPR-associated transposon development for gene therapy in cystic fibrosis (National Institute of General Medical Sciences). Additional recent work spans influenza A virus immune escape mechanisms through N-glycosylation analysis (National Institute of Allergy and Infectious Diseases), MCL-1 metabolic roles in acute myeloid leukemia stem cell maintenance (National Cancer Institute), and regulatory T cell metabolic reprogramming in tumor immunity (National Institute of Allergy and Infectious Diseases). The organization also conducts applied research on antibiotic resistance, including small-molecule CLPP activators for biofilm infections and tofacitinib analogs as oxacillin potentiators against methicillin-resistant Staphylococcus aureus.

Federal customer concentration clusters heavily with NIH component institutes. The National Cancer Institute dominates with 15 awards, followed by the National Institute of Allergy and Infectious Diseases with 11 awards. The National Heart Lung and Blood Institute, National Institute for Minority Health and Health Disparities, and National Institute of Neurological Disorders and Stroke account for 10 additional awards, covering 88% of the recent award footprint. Work is performed at the organization's Memphis, Tennessee headquarters.

Activity has remained steady in the past five years, ranging from five to eight awards annually, with six awards in 2026 and two in 2027 to date. Eight awards with ultimate completion dates falling within the next twenty-four months face recompete in that window. Sub-recipient engagement is rooted in Emory University partnerships, where the organization participates in grants focused on health disparities in childhood cancer survivors, sickle cell disease immunology, and influenza virus immune dynamics. Combined potential value across all awards stands at $5.9 million, with individual NIH project grants typically ranging from $146 thousand to several hundred thousand dollars per year over multi-year performance periods.